Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-038427
Filing Date
2025-03-13
Accepted
2025-03-13 11:24:30
Documents
109
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K mcrb-20241231.htm   iXBRL 10-K 4019619
2 EX-4.2 mcrb-ex4_2.htm EX-4.2 27419
3 EX-19.1 mcrb-ex19_1.htm EX-19.1 142016
4 EX-23.1 mcrb-ex23_1.htm EX-23.1 3854
5 EX-31.1 mcrb-ex31_1.htm EX-31.1 12533
6 EX-31.2 mcrb-ex31_2.htm EX-31.2 12817
7 EX-32.1 mcrb-ex32_1.htm EX-32.1 8497
8 EX-32.2 mcrb-ex32_2.htm EX-32.2 7716
9 EX-97.1 mcrb-ex97_1.htm EX-97.1 33865
  Complete submission text file 0000950170-25-038427.txt   15907224

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20241231.xsd EX-101.SCH 2351879
112 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20241231_htm.xml XML 2654775
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37465 | Film No.: 25734453
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)